A joint study conducted by analysts from Medable and the Center for the Study of Drug Development points toward shorter cycle times, cost savings, and more.
In a partnership with Medable, a center at the university discovered costs linked to investing in decentralized studies far outweigh the eventual benefits.
More than half of new drug approvals last year were for rare diseases – which face long cycle times and other operational challenges that are necessitating the rapid adoption of new solutions, per a recent Tufts report.
Saama and Tufts are teaming up to examine how sponsors and CROs are using automation and information technology in an aim to identify new solutions and optimize drug development.